Related Experiment Video
Updated: May 9, 2026

Motor and Hippocampal Dependent Spatial Learning and Reference Memory Assessment in a Transgenic Rat Model of Alzheimer's Disease with Stroke
Published on: March 22, 2016
Targeting Shared Mechanisms in Atherosclerosis and Alzheimer's Disease
Devesh B Chaudhari1, Kalyani Barve1
1Department of Pharmacology, Shobhaben Pratapbhai Patel School of Pharmacy & Technology Management, SVKM's Narsee Monjee Institute of Management Studies (NMIMS) Deemed-to-be-University, Maharashtra, Vile Parle (W), Mumbai, India.
Insights
Atherosclerosis and Alzheimer's Disease share inflammatory and metabolic pathways. Targeting these common mechanisms, like the NLRP3 inflammasome, offers potential dual therapeutic benefits for both conditions.
Area of Science:
- Neuroscience
- Cardiovascular Science
- Immunology
Background:
- Atherosclerosis and Alzheimer's Disease share pathological hallmarks including inflammation, oxidative stress, and lipid dysregulation.
- Vascular dysfunction in atherosclerosis exacerbates amyloid-beta (Aβ) plaque accumulation in Alzheimer's Disease by impairing cerebral blood flow and Aβ clearance.
Purpose of the Study:
- To review shared pathophysiological pathways between atherosclerosis and Alzheimer's Disease.
- To highlight the potential of targeting common molecular mechanisms for dual therapeutic strategies.
Main Methods:
- Review of preclinical studies and emerging therapeutic agents.
- Examination of key molecular players: NLRP3 inflammasome, Receptor for Advanced Glycation End Products, and apolipoprotein E4.
- Analysis of microRNA-based therapies and lipid metabolism modulators.
Main Results:
- NLRP3 inflammasome inhibitors (e.g., MCC950) and microRNA therapies (e.g., miR-146a) show promise in preclinical models.
- Lipid metabolism modulators (e.g., T0901317, Anacetrapib) offer potential dual cardiovascular and neurological benefits.
- Challenges include Blood-Brain Barrier permeability, genetic variability, and limited clinical data.
Conclusions:
- Targeting shared pathways like inflammation and lipid metabolism presents a promising therapeutic avenue for both atherosclerosis and Alzheimer's Disease.
- Multimodal therapies combining anti-inflammatory, lipid-regulatory, and antioxidant strategies are recommended.
- Personalized medicine approaches leveraging advanced molecular and imaging techniques are crucial for future treatment development.
Abstract:
Atherosclerosis and Alzheimer's Disease are two significant health concerns characterised by overlapping pathophysiological mechanisms, including chronic inflammation, oxidative stress, and lipid metabolism dysregulation. Impaired vascular integrity in atherosclerosis enhances the accumulation of Aβ plaque in the brain by reducing cerebral perfusion and compromising the clearance of Aβ. This review examines the shared pathways linking these conditions, emphasizing the role of the NLRP3 inflammasome, Receptor for Advanced Glycation End Products, and the apolipoprotein E4 allele in exacerbating vascular dysfunction that promotes neurodegeneration. The interplay between these factors underscores the potential of targeting these common pathways as a therapeutic strategy for both diseases. In preclinical studies, emerging treatments, NLRP3 inflammasome inhibitors like MCC950 and CY-09, show promise in mitigating both arterial plaque formation and neuronal amyloid deposition, while innovative microRNA-based therapies targeting miR-146a and miR-155 offer novel approaches to reduce inflammatory responses. Additionally, modulation of lipid metabolism through liver X receptor agonists like T0901317 and cholesteryl ester transfer protein inhibitors, including Anacetrapib, offers potential dual benefits for cardiovascular and neurological health. However, challenges such as restricted BBB permeability, genetic and sex variability, and limited long-term clinical evidence continue to constrain the effectiveness of dual-targeted therapeutic approaches. Future perspectives suggest integrating multi-- modal therapies that combine anti-inflammatory, lipid-regulatory, and antioxidant strategies to effectively address these interrelated diseases. Advancements in molecular biology and imaging techniques may facilitate the development of personalised medicine approaches, ultimately improving outcomes for patients suffering from both atherosclerosis and Alzheimer's Disease.
Related Concept Videos
Alzheimer Disease ll: Pathophysiology
Alzheimer's Disease: Treatment
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer Disease l: Introduction
Dementia l: Introduction
Pharmacogenomics: Identification of New Drug Targets
